GENOWAY overview

SIGMA-ALDRICH AND GENOWAY EXPAND THEIR CRISPR/CAS9 STRATEGIC ALLIANCE PR Newswire ST. LOUIS, Mo. and LYON, France, Sept. 8, 2022 ST. LOUIS, Mo. and LYON, France , Sept. 8, 2022 /PRNewswire/ -- Sigma-Aldrich Co LLC (a subsidiary of Merck KGaA, Darmstadt, Germany ), a leading science and technology company and provider of genome editing research tools, and genOway the leading company in the preclinical research model space, today announced a new structure to their 2018 strategic alliance in the...

SIGMA-ALDRICH AND GENOWAY EXPAND THEIR CRISPR/CAS9 STRATEGIC ALLIANCE PR Newswire ST. LOUIS, Mo. and LYON, France, Sept. 8, 2022 ST. LOUIS, Mo. and LYON, France , Sept. 8, 2022 /PRNewswire/ -- Sigma-Aldrich Co LLC (a subsidiary of Merck KGaA, Darmstadt, Germany ), a leading science and technology company and provider of genome editing research tools, and genOway the leading company in the preclinical research model space, today announced a new structure to their 2018 strategic alliance in the...

genOway and Merck Strengthen CRISPR/Cas9 Strategic Alliance by Extending Their Partnership to All Animal Cell Models genOway acquires additional rights to develop all animal cell models using the CRISPR/Cas9 system PR Newswire LYON, France, Jan. 7, 2020 LYON, France , Jan. 7, 2020 /PRNewswire/ -- genOway, a public company and leader in developing genetically modified research models, today announced an important milestone in extending its strategic alliance with Merck, a leading science and...

genOway and Merck Strengthen CRISPR/Cas9 Strategic Alliance by Extending Their Partnership to All Animal Cell Models PR Newswire LYON, France, Jan. 7, 2020 genOway acquires additional rights to develop all animal cell models using the CRISPR/Cas9 system LYON, France , Jan. 7, 2020 /PRNewswire/ -- genOway, a public company and leader in developing genetically modified research models, today announced an important milestone in extending its strategic alliance with Merck, a leading science and...

genOway and Merck Strengthen CRISPR/Cas9 Strategic Alliance by Extending Their Partnership to All Animal Cell Models PR Newswire LYON, France, Jan. 7, 2020 genOway acquires additional rights to develop all animal cell models using the CRISPR/Cas9 system LYON, France , Jan. 7, 2020 /PRNewswire/ -- genOway, a public company and leader in developing genetically modified research models, today announced an important milestone in extending its strategic alliance with Merck, a leading science and...

MilliporeSigma and genOway Form CRISPR/Cas9 Strategic Alliance to Develop Rodent Models PR Newswire BURLINGTON, Mass., Dec. 10, 2018 - genOway to acquire exclusive rights to MilliporeSigma's foundational genome-editing patents to produce, sell rodent models - New technologies and solutions to be developed using CRISPR/Cas9 to accelerate delivery of better drugs to patients BURLINGTON, Mass. , Dec. 10, 2018 /PRNewswire/ -- MilliporeSigma , a leader in genome editing, today announced a strategic...

VIDEO FINANCIAL REPORTING Why invest in is the first financial video platform where you can easily search through thousands of videos describing global ......